Pillstats
Rx only · Suspension · Rectal

Mesalamine

Brands: Rowasa · Sfrowasa Sulfite-Free Formulation · Mesalamine

5 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US6 NDCs
5 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)52582
US makers5 labelers
Packages10
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.052$0.104$0.156$0.208Mar 2025Apr 2026Jul 2026
$0.127
Latest avg · Jul 22, 2026
-30%
Since Mar 19, 2025
5
Active US suppliers
60%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

4779541.4K1.9K2025 Q12025 Q22025 Q32025 Q42026 Q1
1.1K
Rx · 2026 Q1
1.7M
Units dispensed
-31%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it5 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Viatris Specialty LLCunknown4SUPPLYING
Bryant Ranch Prepackrepackager2SUPPLYING
Encube Ethicals, Inc.unknown2SUPPLYING
ANI Pharmaceuticals, Inc.unknown1SUPPLYING
KLM Laboratories Private Limitedunknown1SUPPLYING

Regulatory & supply events

No recalls, shortages, or registration changes on record for this drug concept.